Insulin pump therapy and continuous glucose monitoring in adults with type 2 diabetes: where are we now?
Technology in diabetes is rapidly evolving, with the aim of helping affected people to safely optimize their blood glucose control. New technologies are now considered as an essential tool for managing glycemia predominantly in people with type 1 diabetes, and clinical trials have demonstrated that...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Open Exploration Publishing Inc.
2020-10-01
|
Series: | Exploration of Medicine |
Subjects: | |
Online Access: | https://www.explorationpub.com/Journals/em/Article/100121 |
id |
doaj-d505b06daa02426a9a0394c1ffa9f46d |
---|---|
record_format |
Article |
spelling |
doaj-d505b06daa02426a9a0394c1ffa9f46d2021-06-24T01:45:06ZengOpen Exploration Publishing Inc.Exploration of Medicine2692-31062020-10-011531433010.37349/emed.2020.00021Insulin pump therapy and continuous glucose monitoring in adults with type 2 diabetes: where are we now?Erika Pedone0https://orcid.org/0000-0002-2588-6528Andrea Laurenzi1https://orcid.org/0000-0002-6073-5098Agnese Allora2Andrea Mario Bolla3https://orcid.org/0000-0001-9366-4081Amelia Caretto4https://orcid.org/0000-0003-1153-6700Vita-Salute San Raffaele University, 20132 Milan, ItalyDepartment of Internal Medicine, IRCCS San Raffaele Scientific Institute, 20132 Milan, ItalyVita-Salute San Raffaele University, 20132 Milan, ItalyDepartment of Internal Medicine, IRCCS San Raffaele Scientific Institute, 20132 Milan, ItalyDepartment of Internal Medicine, IRCCS San Raffaele Scientific Institute, 20132 Milan, ItalyTechnology in diabetes is rapidly evolving, with the aim of helping affected people to safely optimize their blood glucose control. New technologies are now considered as an essential tool for managing glycemia predominantly in people with type 1 diabetes, and clinical trials have demonstrated that in these subjects the use of continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) systems are associated with improved glycemic control along with a better quality of life. Literature regarding technologies and type 2 diabetes is relatively lacking, but innovations may have an important role also in the management of these patients. Some studies in adults with type 2 diabetes have shown benefits with the use of CGM in terms of glycemic variability and improved therapeutic adjustments. Clinical trials about CSII and CGM use in type 2 diabetes may have some pitfalls and future studies are needed to assess how these advanced systems could improve clinical outcomes and also ensure cost-effectiveness in this population. In this narrative review, we aim to highlight the most relevant studies on this topic and to focus on the potential role of new technological devices in type 2 diabetes management.https://www.explorationpub.com/Journals/em/Article/100121continuous glucose monitoringcontinuous subcutaneous insulin infusioncost-effectivenessmultiple daily injectionhypoglycemiatype 2 diabetesdiabetes technology |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Erika Pedone Andrea Laurenzi Agnese Allora Andrea Mario Bolla Amelia Caretto |
spellingShingle |
Erika Pedone Andrea Laurenzi Agnese Allora Andrea Mario Bolla Amelia Caretto Insulin pump therapy and continuous glucose monitoring in adults with type 2 diabetes: where are we now? Exploration of Medicine continuous glucose monitoring continuous subcutaneous insulin infusion cost-effectiveness multiple daily injection hypoglycemia type 2 diabetes diabetes technology |
author_facet |
Erika Pedone Andrea Laurenzi Agnese Allora Andrea Mario Bolla Amelia Caretto |
author_sort |
Erika Pedone |
title |
Insulin pump therapy and continuous glucose monitoring in adults with type 2 diabetes: where are we now? |
title_short |
Insulin pump therapy and continuous glucose monitoring in adults with type 2 diabetes: where are we now? |
title_full |
Insulin pump therapy and continuous glucose monitoring in adults with type 2 diabetes: where are we now? |
title_fullStr |
Insulin pump therapy and continuous glucose monitoring in adults with type 2 diabetes: where are we now? |
title_full_unstemmed |
Insulin pump therapy and continuous glucose monitoring in adults with type 2 diabetes: where are we now? |
title_sort |
insulin pump therapy and continuous glucose monitoring in adults with type 2 diabetes: where are we now? |
publisher |
Open Exploration Publishing Inc. |
series |
Exploration of Medicine |
issn |
2692-3106 |
publishDate |
2020-10-01 |
description |
Technology in diabetes is rapidly evolving, with the aim of helping affected people to safely optimize their blood glucose control. New technologies are now considered as an essential tool for managing glycemia predominantly in people with type 1 diabetes, and clinical trials have demonstrated that in these subjects the use of continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) systems are associated with improved glycemic control along with a better quality of life. Literature regarding technologies and type 2 diabetes is relatively lacking, but innovations may have an important role also in the management of these patients. Some studies in adults with type 2 diabetes have shown benefits with the use of CGM in terms of glycemic variability and improved therapeutic adjustments. Clinical trials about CSII and CGM use in type 2 diabetes may have some pitfalls and future studies are needed to assess how these advanced systems could improve clinical outcomes and also ensure cost-effectiveness in this population. In this narrative review, we aim to highlight the most relevant studies on this topic and to focus on the potential role of new technological devices in type 2 diabetes management. |
topic |
continuous glucose monitoring continuous subcutaneous insulin infusion cost-effectiveness multiple daily injection hypoglycemia type 2 diabetes diabetes technology |
url |
https://www.explorationpub.com/Journals/em/Article/100121 |
work_keys_str_mv |
AT erikapedone insulinpumptherapyandcontinuousglucosemonitoringinadultswithtype2diabeteswherearewenow AT andrealaurenzi insulinpumptherapyandcontinuousglucosemonitoringinadultswithtype2diabeteswherearewenow AT agneseallora insulinpumptherapyandcontinuousglucosemonitoringinadultswithtype2diabeteswherearewenow AT andreamariobolla insulinpumptherapyandcontinuousglucosemonitoringinadultswithtype2diabeteswherearewenow AT ameliacaretto insulinpumptherapyandcontinuousglucosemonitoringinadultswithtype2diabeteswherearewenow |
_version_ |
1721361857805025280 |